HIV-protease inhibitors potentiate the activity of carfilzomib in triple-negative breast cancer.

Publication

HIV-protease inhibitors potentiate the activity of carfilzomib in triple-negative breast cancer.

Journal Paper/Review - Jul 5, 2024

Besse Andrej, Sedlarikova Lenka, Büchler Lorina, Kraus Marianne, Yang Chieh-Hsiang, Strakova Nicol, Soucek Karel, Navratil Jiri, Svoboda Marek, Welm Alana L, Jörger Markus, Driessen Christoph, Besse Lenka

Citation

Besse A, Sedlarikova L, Büchler L, Kraus M, Yang C, Strakova N, Soucek K, Navratil J, Svoboda M, Welm A, Jörger M, Driessen C, Besse L. HIV-protease inhibitors potentiate the activity of carfilzomib in triple-negative breast cancer. Br J Cancer 2024

Project

In vitro proteotoxic synergism of nelfinavir and carfilzomib in solid cancer cell lines

Type

Journal Paper/Review (English)

Journal

Br J Cancer 2024

Publication Date

Jul 5, 2024

Issn Electronic

1532-1827

Brief description/objective

Resistance to chemotherapy is a major problem in the treatment of patients with triple-negative breast cancer (TNBC). Preclinical data suggest that TNBC is dependent on proteasomes; however, clinical observations indicate that the efficacy of proteasome inhibitors in TNBC may be limited, suggesting the need for combination therapies.